Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excretion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

NCT06004960
View directory record Official record
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
[14C]CCX168
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabeled Study of CC-220 in Healthy Male Subjects

NCT03294603
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-220, [14C]
Drug · Radiation
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 19, 2026, 1:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Working Inside for Smoking Elimination

NCT01122589
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Smoking
Interventions
Motivational Interviewing/CBT, CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)
Behavioral · Other
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

NCT05847439
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]BMS-986419
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 19, 2026, 1:40 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

NCT02637934
View directory record Official record
Conditions
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions
[18F]FluorThanatrace, PET/CT imaging sessions
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

NCT02347098
View directory record Official record
Conditions
Acute Coronary Artery Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Neostigmine and Glycopyrrolate

NCT04027972
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

NCT02570373
View directory record Official record
Conditions
Healthy
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Urine Chloride/Creatinine Ratio for Estimation of Urine Sodium

NCT00324883
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 19, 2026, 1:40 PM EDT
Active, not recruiting Phase 4 Interventional

Kebele Elimination of Trachoma for Ocular Health

NCT03335072
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
320,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Transdermal Administration by a Novel Wireless Iontophoresis Device

NCT06351852
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 19, 2026, 1:40 PM EDT
Not listed Phase 4 Interventional

The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study

NCT01323608
View directory record Official record
Conditions
Thalassemia Major
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT03408470
View directory record Official record
Conditions
Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions
TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

NCT04866225
View directory record Official record
Conditions
Healthy Participants
Interventions
Oral [14C]PF-06865571, Oral PF-06865571, IV [14C]PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

NCT01969994
View directory record Official record
Conditions
ADME
Interventions
Controlled dietary background, (-)-[2-14C]epicatechin intake
Other
Lead sponsor
The Institutes for Pharmaceutical Discovery, LLC
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

NCT00499928
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

NCT00426140
View directory record Official record
Conditions
Advanced Malignancies, Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 19, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services

NCT06128304
View directory record Official record
Conditions
HIV, Cervical Cancer
Interventions
Core Implementation strategies, Core+ Enhanced Implementation Strategies
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years to 64 Years · Female only
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

NCT02676830
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-312 100 mg, K-312 100 ug C14 IV
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
25 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 19, 2026, 1:40 PM EDT
Completed No phase listed Observational

Transmission of Chronic Hepatitis C in Pregnancy

NCT03570112
View directory record Official record
Conditions
Hepatitis C, Pregnancy Complications, Vertical Disease Transmission
Interventions
SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

NCT05074134
View directory record Official record
Conditions
Healthy
Interventions
[14C]-TNP-2092
Drug
Lead sponsor
TenNor Therapeutics Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

NCT05652257
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-brensocatib
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 19, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Autonomic Recalibration

NCT06603168
View directory record Official record
Conditions
Chronic Pain (Back / Neck), Autonomic Dysregulation
Interventions
Autonomic Recalibration Treatment
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 1:40 PM EDT